Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.31 |
| ▸ | USP2 | O75604 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9333754 | 0.81 | KDM4E (0.40) | CYP2D6CYP2C19TSHRUSP2LMNA | |
| SCHEMBL28992619 | 0.81 | TDP1 (0.36) | CYP2D6CYP2C19TDP1TSHRCYP3A4 | |
| SCHEMBL17311783 | 0.79 | TSHR (0.38) | CYP2D6CYP2C19TDP1TSHRCYP3A4 | |
| SCHEMBL28567442 | 0.79 | USP2 (0.35) | CYP2D6CYP2C19TSHRUSP2LMNA | |
| SCHEMBL4564777 | 0.78 | LMNA (0.33) | TDP1TSHRCYP3A4USP2MAPT | |
| SCHEMBL9352668 | 0.78 | TGFBR1 (0.35) | CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL11117444 | 0.77 | KDM4E (0.37) | CYP2D6CYP2C19TSHRLMNA | |
| Phosphoric Acid SCHEMBL2993370 | 0.76 | KDM4E (0.36) | CYP2D6CYP2C19SMN1; SMN2LMNA | |
| SCHEMBL29725187 | 0.76 | CYP2D6 (0.37) | CYP2D6CYP2C19TDP1TSHRCYP3A4 | |
| Methacrylic Acid SCHEMBL5082927 | 0.76 | CYP2D6 (0.34) | CYP2D6CYP2C19TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070265460-A1 | PROCESS FOR THE PRODUCTION OF (TRIMETHYLSILYLOXY)SILYLALKYLGLYCEROL METHACRYLATES | JOHNSON & JOHNSON VISION CARE INC. | 2007-11-15 | — | — | US | disclosed |
| EP-1791848-A1 | PROCESS FOR THE PRODUCTION OF (TRIMETHYLSILYLOXY)SILYLALKYLGLYCEROL METHACRYLATES | Johnson and Johnson Vision Care, Inc. (US) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006026245-A1 | PROCESS FOR THE PRODUCTION OF (TRIMETHYLSILYLOXY)SILYLALKYLGLYCEROL METHACRYLATES | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2006-03-09 | — | — | WO | disclosed |
| US-20060047134-A1 | Process for the production of (trimethylsilyloxy)silylalkylglycerol methacrylates | JOHNSON & JOHNSON VISION CARE INC. | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265460-A1 | PROCESS FOR THE PRODUCTION OF (TRIMETHYLSILYLOXY)SILYLALKYLGLYCEROL METHACRYLATES | SGMS2, SGMS1, SMS | CYP2D6 2311/4885CYP2C19 1381/4885TDP1 4007/4885 |
| US-20060047134-A1 | Process for the production of (trimethylsilyloxy)silylalkylglycerol methacrylates | SGMS2, SGMS1, SMS | CYP2D6 2311/4885CYP2C19 1381/4885TDP1 4007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.